Combinations May Combat PARP Resistance


Combining PARP inhibitors with another kind of agent may be key in overcoming resistance.

The implementation of PARP inhibitors is one of the most exciting additions to the treatment of gynecologic cancer, said Leslie M. Randall, MD, MAS, associate professor in the Division of Gynecologic Oncology at the University of California in Irvine.

However, many patients become resistant to the drugs and progress. Combinations, such as a PARP inhibitor plus an immunotherapy agent or PI3K inhibitor, are now being explored to overcome this resistance and lead to better outcomes.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.